Reuters logo
BRIEF-Exelixis announces positive results from phase 2 CABOSUN trial of Cabozantinib vs Sunitinib
2016年10月11日 / 下午2点02分 / 1 年前

BRIEF-Exelixis announces positive results from phase 2 CABOSUN trial of Cabozantinib vs Sunitinib

Oct 11 (Reuters) - Exelixis Inc :

* Cabozantinib met primary endpoint of improving progression-free survival as compared to Sunitinib

* Exelixis announces positive results from phase 2 CABOSUN trial of Cabozantinib versus Sunitinib in previously untreated advanced renal cell carcinoma presented at ESMO 2016

* Based on these results, Exelixis plans to submit a supplemental new drug application (SNDA) for Cabozantinib Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below